Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 114 matching trials from the live ClinicalTrials.gov search.
Conditions
Heart Transplant Failure and Rejection
Interventions
The Prospera™ Test
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Conditions
Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Peutz-Jeghers Syndrome
Interventions
Everolimus
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
Conditions
Actinic Keratosis, Organ or Tissue Transplant; Complications
Interventions
5-Fluorouracil
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Advanced Cutaneous Squamous Cell Carcinoma
Interventions
Ruxolitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions
Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes
Biological
Lead sponsor
Jessie L. Alexander
Other
Eligibility
1 Month to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Palo Alto, California
Conditions
Epstein-Barr Virus, Cytomegalovirus Infections, Adenovirus, BK Virus Infection, Immune Deficiency
Interventions
Rapidly generated virus specific T (R-MVST) cells
Drug
Lead sponsor
Monica Bhatia
Other
Eligibility
3 Months to 26 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Respiratory Syncytial Virus Infections
Interventions
Adjuvanted RSVPreF3 vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Lexington, Kentucky • St Louis, Missouri • Omaha, Nebraska + 3 more
Conditions
Immunosuppression, COVID-19
Interventions
NVX-CoV2372
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Interventions
EBV-specific T cells (EBV-CTLs)
Biological
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
Not listed
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Lymphocytic Leukemia, Lymphoma
Interventions
Biological/Genetically Modified T cells, Cyclophosphamide-based chemotherapy
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Kidney Diseases, Kidney Transplant
Interventions
Human Papilloma Virus vaccine (GARDASIL 9)
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Graft vs Host Disease, Kidney Transplantation
Interventions
Sirolimus (RAPAMUNE)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 10 more
Conditions
Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
Interventions
RP1, intra-tumoral injection, oncolytic virus
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 20 more
Conditions
Solid Organ Transplant Recipients, Parent(s)/Guardian of Referenced Transplant Recipients
Interventions
Assessment of adherence, mental health, behavioral, quality of life and biological constructs
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
Conditions
Complications of Transplanted Organs and Tissue
Interventions
Psychologist Support, Pediatric Certified Diabetes Educators (CDEs) Support
Behavioral
Lead sponsor
Emory University
Other
Eligibility
1 Year to 18 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Solid Organ Transplant
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Chicago, Illinois • Charlotte, North Carolina • Milwaukee, Wisconsin
Conditions
Cytomegalovirus Infections
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Months to 16 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
6
States / cities
Los Angeles, California • Indianapolis, Indiana • Ann Arbor, Michigan + 3 more
Not listed No phase listed Observational

Comparison of Solid Organ Transplant

NCT04055922
Conditions
Gram-Negative Bacterial Infections, Gram-negative Bacteremia, Multidrug-Resistant Organism, Hospital-acquired Pneumonia, Healthcare-associated Pneumonia
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Recruiting Not applicable Interventional

Abdominal Wall Transplant

NCT03310905
Conditions
Transplant;Failure,Kidney, Transplant; Failure, Liver, Transplant; Failure, Bowel, Abdominal Wall Defect, Abdominal Wall Fistula, Abdominal Wall Hernia, Abdominal Wall Injury
Interventions
Abdominal Wall Transplant with another solid organ transplant, Abdominal Wall Transplant alone
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Infection in Solid Organ Transplant Recipients
Interventions
Solid organ transplant
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Interventions
CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania